News

Kala Pharmaceuticals chairman, president and CEO Mark Iwicki said: “We are pleased to be partnering with Athyrium and to have their support and confidence in INVELTYS for the

As per terms of the deal, Roche will secure worldwide and exclusive license from GO Therapeutics for cancer-specific targeting antibodies. The license will allow Roche to develop and

The newly licensed Xonvea, which is a combination of doxylamine and pyridoxine, will be available across the country for women having NVP where conservative management was not successful.

Feraccru already has an approval for the indication in adults in the European Union. In Switzerland, the drug has been approved for the treatment of iron deficiency anaemia

Under the terms of the agreement, Dr. Reddy’s sold all the issued and outstanding membership interests in Dr. Reddy’s Laboratories Tennessee, LLC and certain related assets. Dr. Reddy’s

The facility, which includes development and manufacturing capabilities for novel respiratory products, complements the inhalation development expertise offered by the Recipharm team in Research Triangle Park, North Carolina.

The results were presented today at the annual congress of the International Sepsis Forum in Bangkok. Septic shock is the ultimate complication of sepsis and currently constitutes an

With the financing, KSQ will advance its first drug program into the clinic within the next 18 months and up to three additional oncology drug programs into IND-enabling

Libtayo is a fully-human monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein-1), and is claimed to be the first and only treatment specifically